ARS Pharmaceuticals, Inc. SPRY Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s return on assets?
- ARS Pharmaceuticals, Inc. (SPRY) reported return on assets of -64.4% in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s return on assets changed year-over-year?
- ARS Pharmaceuticals, Inc.'s return on assets decreased by 1041.6% year-over-year, from -5.6% to -64.4%.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s return on assets?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s return on assets has grown at a 35.6% compound annual growth rate (CAGR), from -20.2% to -50.5%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.